



EVALUATION AND VALIDATION OF A UPLC METHOD FOR THE ESTIMATION OF ARIPIPRAZOLE IN TABLET DOSAGE FORM

Reshma*¹, Dr. Osman Ahmed¹, Syeda Rakhshinda Zareen¹, Mohammed Sayeed Uddin¹ and Dr. Anas Rasheed²

¹Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

²CSO, Gaelib Medications Private Limited, Hyderabad.

***Corresponding Author: Reshma**

Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

Article Received on 08/12/2022

Article Revised on 28/12/2022

Article Accepted on 18/01/2023

ABSTRACT

A medication used to treat psychosis will modify the functioning of particular brain chemicals. Patients with mental disorders such as schizophrenia and manic depression may find relief from the drug's ability to alleviate their symptoms. The FDA-approved atypical antipsychotic aripiprazole has a mechanism of action that is unique from that of other FDA-approved atypical antipsychotics.


KEYWORDS: Aripiprazole, schizophrenia and FDA.

INTRODUCTION

Aripiprazole is an antipsychotic medication, works by changing the actions of chemicals in the brain. It is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). Aripiprazole possess a different mechanism of action which is different from other FDA – approved atypical antipsychotics approved by Food and Drug Administration. Instead of acting as an antagonist at D₂ receptor it acts as a partial agonist at the D₂ receptor. It also acts as the partial agonist at the 5-HT_{1A} receptor but exhibits the role of the antagonist at 5-HT_{2A} receptor similar to that of the other atypical antipsychotics.

Aripiprazole also possess high affinity towards 5-HT₇ receptor (acts as antagonist) and 5-HT_{2C} receptor (acts as a partial agonist). Its action on the 5-HT₇ receptor and 5-HT_{2C} receptor is found to be the main cause of weight gain of the patient during the treatment period. Aripiprazole also possess moderate affinity for histaminergic, α-adrenergic, dopaminergic receptors and serotonin transporter. It has a very less affinity for muscarinic acetyl choline receptors. The main aim and objective of this work is to perform the physical, chemical characterization (in-vitro dissolution profile) and accelerated stability studies for the optimized lab scale batch to formulate a stable and robust formulation of aripiprazole immediate release tablets of strength 30mg, which is used in the treatment of schizophrenia and bipolar disorders.

CHEMICAL STRUCTURE OF ARIPIPRAZOLE



Weight: 383.51 g·mol⁻¹

Chemical Formula C₂₃H₂₇Cl₂N₃O₂

IUPAC

7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one

EXPERIMENTAL

METHODOLOGY

Method Validation

What we mean when we talk about "the analytical technique" is the method by which the analysis is carried out. All of the analytical procedures should be spelled out in great detail. The sample, the reference standard, and the reagents, as well as their preparations, the use of the equipment, the development of the calibration curve, the application of the formulas for the calculation, etc. There has been comprehensive validation of the disclosed technique for its specificity, system appropriateness, linearity, accuracy, precision, limit of detection, limit of quantification, and robustness.

RESULTS

Preparation of Standard Stock Solution

Preparation of Diluent

In arrange to achieve partition beneath ideal circumstances taking after an arrangement of exploratory

trials, it is essential to summarize the comes about. A stationary stage such as the Hypersil BDS C18 (100 mm x 2.1 mm, 1.7 m) column was the foremost fitting since it generated symmetrical crests with tall determination and an awfully great affectability, as well as an awfully great determination and affectability. The stream rate

was kept steady at 0.25 mL min⁻¹, coming about in great determination. The response of Aripiprazole to the PDA finder was explored, and it was found that the ideal wavelength was 210 nm, which had the most prominent affectability.

System Precision


Parameters	Aripiprazole
Theoretical plates $\pm$ % RSD	2116.87 $\pm$ 0.45
Asymmetry $\pm$ % RSD	1.04 $\pm$ 0.03
Repeatability (% RSD)	0.16

Method Precision

Replicate	Aripiprazole		
S.No.	Concentration Taken (μ g/ml)	Area	%LC
1	25.68	4546379	98.76%
2		4552065	98.86%
3		4554088	98.65%
4		4556286	98.73%
5		4558256	98.66%
6		4555349	98.89%
Average			98.89%
Std.Dev			0.0920
% RSD			0.09%
Standard weight			25.68mg
Standard potency			98.90 %


Linearity

Aripiprazole		
Linearity level	Concentration in μ g/mL	Area
1	20 μ g/mL	1496456
2	40 μ g/mL	2898635
3	60 μ g/mL	4299345
4	80 μ g/mL	5618534
5	100 μ g/mL	7006228
Correlation co-efficient	0.9997	
Slope	86973.4	
Intercept	4341977.2	



Ruggedness

Aripiprazole			
Ruggedness			
Parameter	Peak Area	% RSD	%LC
Intraday precision	4554165	0.14%	99.76%
	4562378		99.97%
	4567854		100.12%
Inter day precision	4554139	0.14%	99.84%
	4562534		100.03%
	4568069		100.15%
Instrument:1 Acquity HPLC Waters,2695H	4562087	0.13%	99.96%
	4567495		100.12%
	4555187		99.86%
Instrument:2 Agilent Technologies,1290	4562143	0.13%	99.96%
	4567354		99.14%
	4555183		99.78%
Average			99.98
Std.Dev			0.14
%RSD			0.15%

Assay Studies
Sample Control
**EVALUATION OF METHODS****Assay Studies****Calculation formula for Aripiprazole**

$$\% \text{ Assay} = \frac{AT}{AS} \times \frac{W1}{100} \times \frac{1}{25} \times \frac{100}{W2} \times \frac{25}{1} \times \frac{AW}{LC} \times P$$

Aripiprazole

$$\% \text{ Assay of API} = \frac{4558244}{4899318} \times \frac{25.62}{100} \times \frac{1}{25} \times \frac{100}{25.44} \times \frac{25}{1} \times \frac{25.40}{25.42} \times 98.90 = 92.75\%$$

$$\% \text{ Assay of Market} = \frac{4559321}{4899318} \times \frac{25.62}{100} \times \frac{1}{25} \times \frac{100}{25.44} \times \frac{25}{1} \times \frac{25.40}{25.42} \times 98.90 = 92.75\%$$

CONCLUSION

A particular, accurate, and precise high weight fluid chromatography (HPLC) method for the assessment of Aripiprazole in bulk medication and measuring form has been developed. The technique was implemented using Hypersil BDS C18 (100 mm x 2.1 mm, 1.7 m) in an angled mode, using methanol and acetonitrile in a 65:35% v/v ratio in the mobile stage and acetonitrile in the stationary stage. At a wavelength of 254 nm, we were able to determine that the stream rate was 0.1 mL/min and the profluent concentration was 0.01%. The upkeep time was calculated to be 1.1300.005 minutes. The process met all of the ICH (International Conference on Harmonization) requirements for linearity, precision, accuracy, restriction of discovery, and limitation of measurement.

REFERENCES

1. Y. C. Mayur*, Osman Ahmad, V. V.S. Rajendra Prasad, M. N. Purohit, N. Srinivasulu, S. M. Shanta Kumar, "Synthesis of 2-Methyl N¹⁰-Substituted Acridones as Selective Inhibitors of Multidrug Resistance (MDR) Associated Protein in Cancer Cells". Medicinal Chemistry, Bentham Science Publishers, 2008; 4(5): 457-465(9).
2. Osman Ahmed*, Pankaj Sharma, Jaya Sharma, "Synthesis and Pharmacological Study of Azetidinone Derivatives" International Journal of Pharmaceutical Science & Education, 2013; 11-18.
3. Osman Ahmed*, Pankaj Sharma, Jaya Sharma, Dr. Indrajeet Singhvi, "Synthesis and Anticonvulsant Activity of Some Substituted Azetidinone Derivatives" Asian Journal of Pharmaceutical Research and Development, 2013; 5.
4. Osman Ahmed*, Dr. Md Salahuddin, Vinutha. K, Pankaj Sharma. "Design, Synthesis and Biological Evaluation of Some Novel Substituted Thiazolidinone Derivatives as Potent Antihyperglycemic Agents". International Journal of Pharmaceutical Research Scholars, 2013; 2: 3.
5. Osman Ahmed*, Md Salahuddin, Pankaj Sharma, Indrajeet Singhvi "Synthesis and biological investigations of some new thiazolidinone derivatives as anti-tubercular agents", American Journal of Pharmtech Research, 2013; 3: 193-201.
6. Osman Ahmed*, Md. Salahuddin, Iffath Rizwana, M.A.Aleem, Pankaj Sharma, "Synthesis, Characterization and Biological Evaluation of Novel thiazolidinone derivatives as Anti-inflammatory Agents", Indo American Journal of Pharmaceutical Research, 2013; 3(10): 8121-8126.
7. Osman Ahmed*, Pankaj Sharma, Indrajeet Singhvi. "Synthesis and Anti-Hyperglycemic activity of Some Novel Thiazolidinone Derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(02): 1008-1014.
8. Osman Ahmed*, Pankaj Sharma, Indrajeet Singhvi. "Anticonvulsant Activity of Some Novel Substituted Thiazolidinone Derivatives against Maximal Electro Shock Induced Seizure". International Journal of Pharmaceutical Research Scholars, 2014; 3(1): 289-294.
9. Osman Ahmed*, Mohd Haseeb Ur Rahman, Abdul Najeeb, Sk. Md. Noorullah, S.A.Azeez Basha, Design, "Synthesis and Anti- inflammatory activity of certain fused Novel Thienopyrimidines Derivatives", International Journal of Pharmaceutical Research Scholars, 2013; 2(4): 82-87.
10. Syed Aamer Ali, SK Danda, Syed Abdul Azeez Basha, Rasheed Ahmed, Osman Ahmed, Mohd Muqtader Ahmed. "Comparision of uroprotective activity of reduced glutathione with Mesna in Ifosfamide induced hemorrhagic cystitis in rats". Indian Journal of Pharmacology, 2014; 46: 105-108.
11. Osman Ahmed*, Syed Azeemuddin Razvi, T K Md Rayees, M A Nafay Shueb, Md Salahuddin. "Synthesis Characterization and Anti-inflammatory activity of some substituted pyrimidine derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(05): 2301-2306. DOI: 10.1044/1980-iajpr.14369.
12. Osman Ahmed*, Farhana Begum, Nishat Fatima, Md. Salahuddin. "Synthesis and Biological Activity of Some Novel Pyrimidine Derivatives". International Journal of Pharmaceutical Research Scholars, 2014; 3(4): 103-108.
13. Ms. Farhana Begum, Osman Ahmed, Md. Salahuddin, Nishat Fatima. "Synthesis, Characterization and Anti-Hyperglycemic Activity of Novel Pyrimidine Derivatives". Indo American Journal of Pharm Research, 2014; 4(11): 5501-5506. DOI: 10.1044/19 80-iajpr.141042
14. Osman Ahmed*, Mehruq Fatima, Juveriya Parveen, Asma Farheen, Ayesha Binth Saleh, Dr. Syed Mahmood Ahmed. Changes in Pulmonary Function Test (PFT) Before and After Adding Tiotropium Bromide to the Ongoing Therapy of Severe Persistent Asthamatics. Indo American Journal of Pharm Research, 2015; 5(01). DOI: 10.1044/1980-iajpr.141266.
15. Mohd Khader, Mohd Mahboob Shareef, Syeda Huda Noorain, Osman Ahmed. Synthesis, Characterization and Biological Activity of Some Novel Pyrimidine Derivatives. Indo American Journal of Pharm Research, 2015; 5(03).
16. Fayeza Batool, Osman Ahmed, Anas Rasheed. An Assay Method for the Simultaneous Estimation of Acetaminophen and Tramadol using RP-HPLC Technology. Indo American Journal of Pharmaceutical Research, 5(7): 2605-2610.
17. Fayeza Batool, Osman Ahmed, Anas Rasheed. A Stability Indicating Method for the Simultaneous Estimation of Acetaminophen and Tramadol in Pharmaceutical Dosage Form. American Journal of PharmTech Research, 2015; 5(04): 674-683.
18. Humeera Rafeeq, Talath Fatima, Afiya Ansari, Osman Ahmed. Personalized Medicine - A Boon For Treating Rheumatoid Arthritis. Indo American Journal of Pharmaceutical Research, 5(8).

19. Humeera Rafeeq, Osman Ahmed, M.A Khaleq, Samee A, Amer M. Progress In The Treatment of Neuroblastoma. *Indo American Journal of Pharmaceutical Research*, 5(8).
20. Talath Fatima, Osman Ahmed, Amer Mahboob, Afiya Ansari, Amatullah Fathimah. Personalized Medicine - A Review – Progress In The Treatment of Non Small Cell Lung Cancer (NSCLC) In A New Era of Personalised Medicine. *Indo American Journal of Pharmaceutical Research*, 5(8).
21. Talath Fatima*, Osman Ahmed, Afiya Ansari, Amatullah Fathimah, Amer Mahboob. Novel Therapeutic Approaches to a Chronic Inflammatory Disorder – Asthma. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 112-117.
22. Humeera Rafeeq*, Osman Ahmed, Sohail Ali, Mohd Younus, Mohd Bilal. A Review on Mowat-Wilson Disorder, *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 176-181.
23. Humeera Rafeeq*, Osman Ahmed, Fayeeza Ameen, Amreen Sultana, Maryam Fatima. A Review on Harlequin Ichthyosis. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 189-193.
24. Anees Begum*, Osman Ahmed. An Assay Method for the Simultaneous Estimation of Albuterol and Ipratropium Bromide using RP- HPLC Technology. *International Journal of Pharmaceutical Research Scholars*, 2016; 5(4): 33-37.
25. Anas Rasheed*, Osman Ahmed. UPLC Method Optimisation and Validation for the Estimation of Sodium Cromoglycate in Pressurized Metered Dosage Form, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 18-24, <http://dx.doi.org/10.21477/ijapsr.v2i2.7774>
26. Anas Rasheed*, Osman Ahmed. UPLC Method Development and Validation for the Determination of Chlophedianol Hydrochloride in Syrup Dosage Form. *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 25-31, <http://dx.doi.org/10.21477/ijapsr.v2i2.7775>
27. Anas Rasheed*, Osman Ahmed. Validation of a Forced Degradation UPLC Method for Estimation of Beclomethasone Dipropionate in Respules Dosage Form. *Indo American Journal of Pharmaceutical Research*, 2017; 7(05).
28. Anas Rasheed*, Osman Ahmed. Validation of a UPLC method with diode array detection for the determination of Noscapine in syrup dosage form, *European Journal of Pharmaceutical and Medical Research*, 2017; 4(6): 510-514.
29. Anas Rasheed*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Triamcinolone in syrup dosage form. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(4): 200-205.
30. Anas Rasheed*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Pholcodine in bulk dosage form. *European Journal of Biomedical and Pharmaceutical Sciences*, 2017; 4(6): 572-579.